article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

Diabetes 101
article thumbnail

Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO

pharmaphorum

NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief executive Sir Simon Stevens. “We are determined to see UK-wide availability of life-changing type 1 diabetes technology options on the NHS,” she added.

Diabetes 131
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Reach 35 New Countries and Improve Diabetes Care Communication: Viseven Collaborations

Viseven

This company specializes in biopharmaceuticals, diabetes care, obesity care, and other severe chronic diseases. The partnership aims to redesign healthcare professionals’ access and use of critical information about diabetes care. Interested in building your own Digital Content Factory? Let us know!

article thumbnail

Prescribing Success: Dr. Linda Gutierrez-Miller’s Journey to Impactful Clinical Pharmacy and Inspiring Resilience!

Pharmacy Is Right For Me

Additionally, she holds the title of Certified Diabetes Care and Education Specialist (CDCES). Overcoming Barriers Despite the challenges in her current role, including communication barriers due to the diverse linguistic landscape of her clinic, Dr. Gutierrez-Miller remains dedicated to providing the best care possible.

Diabetes 306
article thumbnail

Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes

pharmaphorum

In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Collaborating to prevent diabetes. How can we get that message into communities? Digital tools.

Diabetes 111
article thumbnail

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

article thumbnail

Lilly preps for rollout of its connected diabetes system

pharmaphorum

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular disease and nerve damage affecting the eyes and extremities.